Lai, Chih-ChengChih-ChengLaiChen, Wei-ChihWei-ChihChenKuo, Li-KuoLi-KuoKuoWang, Yao-TungYao-TungWangFu, Pin-KueiPin-KueiFuSHIH-CHI KUFang, Wen-FengWen-FengFangChen, Chin-MingChin-MingChenTu, Chih-YenChih-YenTuCheng, Wen-ChienWen-ChienChengChen, Chia-HungChia-HungChen2023-09-052023-09-052023-07-1400257974https://scholars.lib.ntu.edu.tw/handle/123456789/635088The objective was to compare the clinical efficacy of cefoperazone-sulbactam with piperacillin-tazobactam in the treatment of severe community-acquired pneumonia (SCAP). The retrospective study was conducted from March 1, 2018 to May 30, 2019. Clinical outcomes were compared for patients who received either cefoperazone-sulbactam or piperacillin-tazobactam in the treatment of SCAP. A total of 815 SCAP patients were enrolled. Among them, 343 received cefoperazone-sulbactam, and 472 received piperacillin-tazobactam. Patients who received cefoperazone-sulbactam presented with higher Charlson Comorbidity Index scores. (6.20 ± 2.77 vs 5.72 ± 2.61; P = .009). The clinical cure rates and effectiveness for patients receiving cefoperazone-sulbactam and piperacillin-tazobactam were 84.2% versus 80.3% (P = .367) and 85.4% versus 83.3% (P = .258), respectively. In addition, the overall mortality rate of the cefoperazone-sulbactam group was 16% (n = 55), which was also comparable to the piperacillin-tazobactam group (17.8%, n = 84, P = .572). The primary clinical outcomes for patients receiving cefoperazone-sulbactam were superior compared to those receiving piperacillin-tazobactam after adjusting disease severity status. The clinical efficacy of cefoperazone-sulbactam in the treatment of adult patients with SCAP is comparable to that of piperacillin-tazobactam. After adjusting for disease severity, cefoperazone-sulbactam tended to be superior to piperacillin-tazobactam.enacquired pneumonia | cefoperazone | piperacillin | severe community | sulbactam | tazobactam[SDGs]SDG3journal article10.1097/MD.0000000000034284374435052-s2.0-85164843711https://api.elsevier.com/content/abstract/scopus_id/85164843711